📢 Leukodystrophy Awareness Month takes place throughout the whole month of September and is a time to raise awareness about these devastating rare conditions!

Together 🤝 let’s shine a light💡 and increase understanding of leukodystrophy, a group of rare genetic metabolic disorders affecting the central nervous system. Leukodystrophies are characterized by the abnormal growth of white matter in the brain🧠, causing progressive damage to the brain’s myelin sheath – the protective layers surrounding the nerve fibers of the brain and spinal cord.

At Vivet, we have been granted Orphan Drug Designation (#ODD) by the @European Commission for our gene therapy product, VTX-806, for the treatment of cerebrotendinous xanthomatosis (#CTX). VTX-806 is demonstrating promising pre-clinical data as an alternative treatment option with the potential to bring significant benefits to patients affected by CTX.

Raising awareness of #Leukodystrophies can help improve early diagnosis, fund research, and provide resources to families affected by these conditions.